On July 21, Joinn Laboratories (06127.HK) rose 6.62% in regular trading, reaching HK$24.92 per share, with turnover of HK$211 million.

The rally was driven by the disclosure that Barclays PLC acquired approximately 3.28 million shares of Joinn Laboratories on July 15 at an average price of HK$24.25 per share, totaling approximately HK$79.54 million. Following the purchase, Barclays' total holding rose to roughly 7.29 million shares, representing a 6.12% stake in the company. Additionally, the broader CXO sector extended its rebound, with peers including WuXi Biologics and WuXi AppTec posting gains on the same day, providing sector-wide support.

The institutional endorsement comes amid elevated market attention on Joinn Laboratories following its H1 earnings guidance forecasting net profit growth of 885% to 1,377%, primarily driven by fair value appreciation of biological assets as experimental primate prices surpassed RMB 200,000 per animal. The company's core laboratory services revenue, however, recorded only modest growth amid ongoing competitive pressures.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)